TY - JOUR AU - Pinard, Emmanuel AU - Borroni, Edilio AU - Koerner, Annette AU - Umbricht, Daniel AU - Alberati, Daniela PY - 2018/08/22 Y2 - 2024/03/29 TI - Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient JF - CHIMIA JA - Chimia VL - 72 IS - 7-8 SE - Scientific Articles DO - 10.2533/chimia.2018.477 UR - https://www.chimia.ch/chimia/article/view/2018_477 SP - 477 AB - Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical companies and academic institutions primarily as a potential new approach to treat schizophrenia, a severe and chronic mental illness. More recently, preclinical results have suggested that this approach could also have therapeutic potential for CNS disorders beyond schizophrenia as well as for non-CNS indications. Over the past 17 years, Roche has been a key player in the GlyT1 field with the discovery and development of bitopertin, the most advanced GlyT1 inhibitor to date and the only one which completed Phase III clinical studies for schizophrenia. In this article, we relate the eventful journey of the discovery and development of bitopertin, from project initiation in 2001 to its evaluation today in patients suffering from beta-thalassemia, a monogenic hereditary haematological disorder. ER -